All News

computer screen safety

Cardiovascular and Venous Thromboembolic Risk With JAK Inhibitor Treatment of Skin Disorders

d Jack Cush, MD

A JAMA systematic review and meta-analysis has showed the use of JAK inhibitors (JAKi) in immune-mediated inflammatory skin diseases was not associated with increased risk of all-cause mortality, major adverse cardiovascular events (MACE), or venous thromboembolism (VTE) (compared to the placebo

Read Article
dequervain,tenosynovitis

Optimal Management of de Quervain Tenosynovitis

d Jack Cush, MD

The treatment of de Quervain tenosynovitis (DQT) was examined  by systematic review in JAMA, suggesting that local (US-guided) corticosteroid injection plus a thumb spica immobilization was associated with significant pain-relieving and functional benefits. 

Read Article
hourglass with red sand

Fast track clinics -the future of PMR care?

d Patricia Harkins, MD

Over the past year we have implemented a fast track clinic for PMR at our institution in Dublin. Patients are referred predominantly from primary care, and we aim to see patients within a one to two week window. Without a doubt, patient outcomes are far superior with the instigation of the fast track clinic as part of our service.

Read Article
FDA has approved secukinumab (Cosentyx) for use in adults w/ moderate to severe hidradenitis suppurativa. Recommended dose is 300 mg SC @ wk 0, 1, 2, 3 and 4 and then every 4 weeks thereafter. https://t.co/Pi6RbDbroG https://t.co/AWhbVj2QGa

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA has approved Abatacept to Treat Juvenile Psoriatic Arthritis (JPsA) in patients aged 2 to 17 years. (JPsA) in patients aged 2 to 17 years. This expands the current indications for ABA use in RA, poly JIA, PsA, and GVHD. https://t.co/eAc8Dsyc3b https://t.co/uHJqhEvuPG

Links:

Dr. John Cush RheumNow ( View Tweet)
RheumNow Live registration is NOW OPEN! Early bird pricing through 11/30/2023. Register today! https://t.co/1SjBiM7Daj https://t.co/w2cFcj85r5

Links:

Dr. John Cush RheumNow ( View Tweet)
Choosing steroid sparing therapies in #PMR We have no evidence-based alternative treatment to glucocorticoids in PMR. Few disease-modifying anti-rheumatic drugs, such as methotrexate and leflunomide, are used in daily clinical practice in PMR. https://t.co/zvfAwc7t1z https://t.co/pAJFHF6hOn

Links:

Dr. John Cush RheumNow ( View Tweet)
Blinkers and the Unseen Information Gap in #PMR https://t.co/uZ9qCPmRw9 https://t.co/lrXRdVGNk2

Links:

Dr. John Cush RheumNow ( View Tweet)
#PMR Mythbusters: PMR Gets 100% Better Within 72 hours https://t.co/lezwD0J8pL https://t.co/QluGHHnH3X

Links:

Dr. John Cush RheumNow ( View Tweet)
Why should rheumatologists discuss exercise in #PMR? https://t.co/DBnXetbu2K https://t.co/hfjugw661u

Links:

Dr. John Cush RheumNow ( View Tweet)
Metanalysis of 26 studies (2252) pts w/ HBsAg-/HBcAb+ RA treated with b/tsDMARDs, shows the pooled HBV reactivation rate was 2.0% HBV reactivation higher w/ RTX (9%), ABA (6%), JAKi (1%); none w/ IL-6i or TNF-i More reactivation if pt is HBsAb- (OR=4.56) https://t.co/fSqvkEGbw3 https://t.co/WGCoZ4nQ3d

Links:

Dr. John Cush RheumNow ( View Tweet)
FDA Approves Infliximab Biosimilar for Subcutaneous Use Another infliximab biosimilar has been FDA approved, but this new version of Inflectra can be given subcutaneously for patients with inflammatory bowel disease. https://t.co/YnbisOzf0L https://t.co/9AyxEBpasb

Links:

Dr. John Cush RheumNow ( View Tweet)
Ph 3 360 pt RCT of sarilumab in #GCA was terminated early (COVID). 83 pts Rx'd, only 35%(29) completed. Sustained remission @wk 52: - SAR 200: 6/13 - SAR 150: 3/7 - PBO: 0/6 All had 26wk GC taper Sm sample size & COVID ruined RCT interpretation https://t.co/axOvJGpUti #PMR https://t.co/Xpabxn1IjZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Subcutaneous Biosimilars? Dr. Cush reviews RheumNow's top entries the #PMR Campaign, news, journal reports and regulatory actions. https://t.co/BkKFbv0I64 https://t.co/EABeZxCKYZ

Links:

Dr. John Cush RheumNow ( View Tweet)
Analysis of the NOR-DMARD registry and Vienna #RA cohorts provided novel definitions for an RA flare, requiring an increase of -4.7 on the SDAI or -4.5 on the CDAI Flare definitions correlated with functional and Xray outcomes. https://t.co/f2G2nYyyWT https://t.co/JczDZa9oUf

Links:

Dr. John Cush RheumNow ( View Tweet)

JAMA Review of Knee Pain: - 5% PCP visits for knee pain: - Knee #OA: 654 mill worldwide, mostly >45 yrs age - Patellofemoral OA: < 40 yrs age; Sx: ant knee pain w/ squat - Meniscal tears: 12% adults < 40 yrs; dx by McMurray test & joint line tenderness https://t.co/kf1OOiwIR4 https://t.co/e5hiodDZgn

Links:

Dr. John Cush RheumNow ( View Tweet)
New download available--#PMR Survey Results https://t.co/rfOQxFrO3I https://t.co/l8T7P3tdOb

Links:

Dr. John Cush RheumNow ( View Tweet)
Congrats to the dynamic duo! https://t.co/omc3AeFKTH

Links:

Dr. John Cush RheumNow ( View Tweet)

#PMR Mythbusters: PMR Needs Elevated ESR or CRP https://t.co/GbHSyu24qw https://t.co/yaRa0UIQq1

Links:

Dr. John Cush RheumNow ( View Tweet)
Anti-Phospholipid Antibodies - Infrequent in Certain Groups Among patients with SLE, high titers of anti-phospholipid (aPL) antibodies were most prevalent in whites and Latinos and less so for Black and Asian individuals, researchers found. https://t.co/qQygcS3Ktw https://t.co/FVKlvFuuFn

Links:

Dr. John Cush RheumNow ( View Tweet)
×